Adjunctive, Low-dose tPA in Primary PCI for STEMI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT03335839
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 210 participants
- Registry
-
NCT03335839
-
- Other papers using this trial's data
- Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03335839. Randomized; triple masking; primary purpose treatment. Start 2018-04-01 (actual); primary completion 2024-09-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Adjunctive, Low-dose tPA in Primary PCI for STEMI
- Acronym
- STRIVE
- Condition
- Myocardial Infarction
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- tissue plasminogen activator
- Intervention (Other)
- Saline
- Lead sponsor
- Population Health Research Institute
- Collaborator
- Heart and Stroke Foundation of Canada
Record details
- Record id
cardio:ct-nct03335839- Content hash
9499a509ecd294f0e21184a5f2eb737bf1d3df9213ef94417a438ee7d7750b04